Evidence map›Paper›PMID 23946491›Full record

ArticleThe Journal of biological chemistry2013

The transcription factor Foxf1 binds to serum response factor and myocardin to regulate gene transcription in visceral smooth muscle cells.

April M Hoggatt, Ju-Ryoung Kim, Vladimir Ustiyan, Xiaomeng Ren, Tanya V Kalin, Vladimir V Kalinichenko, B Paul Herring

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Therapeutic Potential of Endothelial Progenitor Cells in Pulmonary Diseases.American journal of respiratory cell and molecular biology · 2021
    Review
  15. Article
  16. Article
  17. Nanoparticle Delivery Systems with Cell-Specific Targeting for Pulmonary Diseases.American journal of respiratory cell and molecular biology · 2021
    Review
  18. Article
  19. American journal of respiratory and critical care medicine · 2021
    Article
  20. Frontiers in cell and developmental biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

April M HoggattFrom the Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana 46202 and.
Ju-Ryoung Kim
Vladimir Ustiyan
Xiaomeng Ren
Tanya V Kalin
Vladimir V Kalinichenko
B Paul Herring
Cincinnati Children's Hospital Medical Center · USIndiana University – Purdue University Indianapolis · USIndiana University School of Medicine

Funding

Fox Transcription Factors in Development of Pulmonary CapillariesR01HL084151 · NHLBI · UNIVERSITY OF CHICAGO · PI KALINICHENKO, VLADIMIR · 2006 to 2018
$4.9M
Visceral smooth muscle-specific gene expressionR01DK061130 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI HERRING, BRIAN PAUL · 2001 to 2011
$2.8M
Role of Foxm1 in Lung Cancer MicroenvironmentR01CA142724 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI KALIN, TANYA · 2010 to 2014
$1.5M
NCI NIH HHS R01 CA142724NHLBI NIH HHS R01 HL084151NIDDK NIH HHS DK61130NIDDK NIH HHS R01 DK061130
6 · The paper itself

Abstract

Smooth muscle cells (SMCs) modulate their phenotype from a quiescent contractile state to a dedifferentiated, proliferative and migratory state during the pathogenesis of many diseases, including intestinal pseudoobstruction. Understanding how smooth muscle gene expression is regulated in these different phenotypic states is critical for unraveling the pathogenesis of these diseases. In the current study we examined the specific roles of Foxf1 in visceral SMC differentiation. Data show that Foxf1 is specifically required for expression of several contractile and regulatory proteins such as telokin, smooth muscle γ-actin, and Cav1.2b in visceral SMCs. Mechanistically, Foxf1 directly binds to and activates the telokin promoter. Foxf1 also directly binds to serum response factor (SRF) and myocardin-related transcription factors (MRTFs). Unlike Foxo4 and Foxq1, which bind to MRTFs and block their interaction with SRF, Foxf1 acts synergistically with these proteins to regulate telokin expression. Knock-out of Foxf1 specifically in SMCs results in neonatal lethality, with mice exhibiting GI tract abnormalities. Mice heterozygous for Foxf1 in SMC exhibited impaired colonic contractility and decreased expression of contractile proteins. These studies together with previous studies, suggest that different forkhead proteins can regulate gene expression in SMCs through modulating the activity of the SRF-myocardin axis to either promote or inhibit differentiation and proliferation thereby altering gastrointestinal contractility and development.

Indexed as

Transcription, GeneticAnimalsAnimals, NewbornAT Rich SequenceBase SequenceBinding SitesCells, CulturedColonContractile ProteinsForkhead Transcription FactorsGene DeletionGene Expression RegulationGene Knockdown TechniquesMiceModels, BiologicalMolecular Sequence DataContractile ProteinsForkhead Transcription FactorsFoxf1 protein, mouseFoxq1 protein, mouseMyocardinMyosin-Light-Chain KinaseNuclear ProteinsPeptide FragmentsSerum Response FactortelokinTrans-ActivatorsForkhead FactorsGene KnockoutGene RegulationGene TranscriptionSmooth MuscletelokinTranscription/Developmental Factors

Identifiers

PMID23946491
PMCPMC3789949
OpenAlexW2075697348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.